Gilead Sciences UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, everyone. Thank you for joining me on this next panel. I'm Michael Yee, Senior Biotechnology Analyst at UBS, and I'm very thrilled to have up on stage with us Andy Dickinson, who's the Chief Financial Officer of Gilead. Andy, congratulations on all the success this year. Your stock's- Thank you. at an all-time high.
Thank you. And we were just talking about the strategy on how you've put the story together, and you're sitting at a particularly unique time here with a lot ahead.
Yeah, absolutely. It's a very exciting time. First of all, thank you for having us.
Yeah. We appreciate your support.
It's great to be here. It is a very exciting time for the company. I mean, we've really spent the better part of the last decade rebuilding the company, rebuilding the pipeline, and you're really starting to see all that come through, both in commercial launches, with three more commercial launches coming behind three that are underway, and then a really strong portfolio below it. So, it's an exciting time for everyone at Gilead and for our shareholders.
Absolutely. So, one of the unique things about Gilead is that you essentially have no meaningful patent expiry or no LOE issues for the next five years.
Really, the next decade. Really, the next decade.
Yeah. Okay. Through 2036 with Biktarvy, yeah.
For the next decade. Recently, your stock has been driven by the growth of HIV, and particularly not only through Biktarvy, but through PrEP. May I just start with the launch of Yeztugo in PrEP? Can you tell us a little bit about how you feel about that success this year?
Sure. How we should be thinking about the Yeztugo and PrEP market?
Sure, yeah. Just to step back for everyone in the room and that is listening, Yeztugo is a once-every-six-month subcutaneous injection for HIV prevention. The phase III studies read out a couple years ago. These are called the PURPOSE studies. Phenomenal efficacy and safety that showed almost, in one study, 100% prevention of HIV transmission across a very large group of people at risk of getting HIV, and the other study was 98%, 99% effective. Really transformative medicine that has raised awareness of HIV prevention. We have had HIV preventions available for the last 10 years. We had two daily oral pills. The first one was TRUVADA, approved a decade ago. DESCOVY was approved, which is the current brand, a daily oral that is a large part of our business and that we will talk about, approved maybe five years ago.
It was really this long-acting injectable that raised awareness. The Yeztugo launch, which started a little bit over a year ago, has gone as well as we could expect. We are targeting $1 billion of sales this year. That is an increase from our guidance at the beginning of the year, that if I remember correctly, was approximately $800 million of sales. Then maybe, Michael, to your question, the most important thing is that all the major launch metrics that we look at are tracking at or ahead of expectations. To give you a couple of examples, we are seeing more people naive to HIV prevention starting on Yeztugo than we would have expected. I think that the expectation at launch is that you would see people that were using the daily orals move, and we are seeing that.
About two-thirds to three-quarters of the people that are moving to Yeztugo are coming off of the daily orals. We are seeing a lot more people that are naive to HIV prevention starting on Yeztugo, which is fantastic. Then the other thing is that we are seeing more people move off of generic TRUVADA. In the switch population, you are seeing a much higher percentage of people moving off the generics onto the branded therapies, which is another really good indication. When you put it all together, we are off to a great start, and we think it is a meaningful growth opportunity for us as we grow the PrEP business over the coming decades.
How has compliance been? How does the durability of this market look like going forward?
Yeah, the durability of the market looks great. Compliance has been really, really strong. When you think about compliance, or we call it persistence, people coming back for their second shot, in the HIV prevention market, these are not people that have HIV. By definition, the persistence or compliance in HIV prevention, there are going to be people coming in and out of therapy over time. If they're in a monogamous relationship, they may not need HIV prevention, et cetera.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
